Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Balancing commercial and public interests.

Furberg CD, Hall MA, Sevick MA.

Curr Control Trials Cardiovasc Med. 2004 Jul 7;5(1):6.

2.

Guidelines, editors, pharma and the biological paradigm shift.

Singh AR, Singh SA.

Mens Sana Monogr. 2007 Jan;5(1):27-30. doi: 10.4103/0973-1229.32176.

3.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
4.

American Society of Clinical Oncology policy statement: oversight of clinical research.

American Society of Clinical Oncology.

J Clin Oncol. 2003 Jun 15;21(12):2377-86. Epub 2003 Apr 29.

PMID:
12721281
5.

[Early achievements of the Danish pharmaceutical industry--8. Lundbeck].

Grevsen JV, Kirkegaard H, Kruse E, Kruse PR.

Theriaca. 2016;(43):9-61. Danish.

PMID:
27491172
6.

Public welfare agenda or corporate research agenda?

Singh A, Singh S.

Mens Sana Monogr. 2005 Mar;3(1):41-80. doi: 10.4103/0973-1229.27878.

7.

[Procedures and methods of benefit assessments for medicines in Germany].

Bekkering GE, Kleijnen J.

Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25. German.

PMID:
19034813
8.

Scientific journals and their authors' financial interests: a pilot study.

Krimsky S, Rothenberg LS, Stott P, Kyle G.

Psychother Psychosom. 1998 Jul-Oct;67(4-5):194-201.

PMID:
9693346
9.

Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Pressel SL, Davis BR, Wright JT, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lusk C, Parks H, Simpson LM, Nwachuku C, Furberg CD; ALLHAT Collaborative Research Group.

Control Clin Trials. 2001 Feb;22(1):29-41.

PMID:
11165421
10.

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.

Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM.

Am J Hypertens. 1996 Apr;9(4 Pt 1):342-60.

PMID:
8722437
11.
12.

Anticancer Drug Development: The Way Forward.

Connors T.

Oncologist. 1996;1(3):180-181.

13.

Conflicts of interest in research involving human beings.

Greco D, Diniz NM.

J Int Bioethique. 2008 Mar-Jun;19(1-2):143-54, 202-3. Review.

PMID:
18664007
14.

The project data sphere initiative: accelerating cancer research by sharing data.

Green AK, Reeder-Hayes KE, Corty RW, Basch E, Milowsky MI, Dusetzina SB, Bennett AV, Wood WA.

Oncologist. 2015 May;20(5):464-e20. doi: 10.1634/theoncologist.2014-0431. Epub 2015 Apr 15.

15.

Risk management frameworks for human health and environmental risks.

Jardine C, Hrudey S, Shortreed J, Craig L, Krewski D, Furgal C, McColl S.

J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. Review.

PMID:
14698953
17.

Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology.

Knox KS, Adams JR, Djulbegovic B, Stinson TJ, Tomor C, Bennet CL.

Ann Oncol. 2000 Dec;11(12):1591-5.

PMID:
11205468
18.

Promoting transparency in pharmaceutical industry-sponsored research.

Ross JS, Gross CP, Krumholz HM.

Am J Public Health. 2012 Jan;102(1):72-80. doi: 10.2105/AJPH.2011.300187. Epub 2011 Nov 28.

19.

Clinical trial transparency: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe.

Rawal B, Deane BR.

Curr Med Res Opin. 2014 Mar;30(3):395-405. doi: 10.1185/03007995.2013.860371. Epub 2013 Nov 11.

PMID:
24168052
20.

Big pharma and health care: unsolvable conflict of interests between private enterprise and public health.

Brezis M.

Isr J Psychiatry Relat Sci. 2008;45(2):83-9; discussion 90-4. Review.

Supplemental Content

Support Center